A bipartisan bill that would shield FDA user fees for drugs and medical devices from sequestration has been introduced in the Senate, following a similar measure recently introduced in the House. AdvaMed President and CEO Stephen Ubl called the Senate move "a win-win-win for FDA, the industry and the millions of American patients who will benefit from more timely access to innovative medical technologies."

Related Summaries